Skip to Content
Biotechnology and health

The Oxford/AstraZeneca vaccine is up to 90% effective, according to interim data

It can also be stored at fridge temperature, making logistics easier.
November 23, 2020
vaccine stock image
AP

The news: Oxford University and AstraZeneca have reported that their covid-19 vaccine is up to 90% effective, according to interim data from the phase 3 trial. The trial found that the vaccine was 70% effective when the data from two different dosing regimes was combined. The first regime, which was 90% effective, used a halved first dose and a full second dose. In the second, which was 62%, participants were given two full doses. There are more than 24,000 volunteers participating in the ongoing trial in the UK, Brazil, and South Africa.

Why it’s promising: The data has yet to be submitted for peer review or publication, but the trial researchers say it suggests the vaccine also reduced asymptomatic transmission. This would mean the vaccine not only helps stop illness but also cuts transmission rates of the virus. No one who received the vaccine was hospitalized or experienced serious illness, and it worked well across all age ranges.

Old school: While Pfizer’s and Moderna’s vaccines are both based on new mRNA technology, the Oxford vaccine is a more traditional adenovirus vaccine. It relies on a weaker version of a virus that causes the common cold in chimps, tweaked so it cannot grow in humans. Adenovirus vaccines are easier to store and transport. That’s why, unlike the Pfizer/BioNTech or Moderna vaccines, which require extremely cold storage, the Oxford vaccine can be stored at fridge temperature (35.6 to 46.4 °F).

Who gets it? Oxford and AstraZeneca have committed to providing the vaccine on a not-for-profit basis for the duration of the pandemic across the world, and permanently for low- and middle-income countries. AstraZeneca already has agreements to supply three billion doses of the vaccine. The UK has ordered 100 million doses of the vaccine, which is enough to vaccinate the majority of its population. If approved, rollout will start before Christmas. Australia has ordered 34 million doses too.

Deep Dive

Biotechnology and health

Scientists are finding signals of long covid in blood. They could lead to new treatments.

Faults in a certain part of the immune system might be at the root of some long covid cases, new research suggests.

This baby with a head camera helped teach an AI how kids learn language

A neural network trained on the experiences of a single young child managed to learn one of the core components of language: how to match words to the objects they represent.

The next generation of mRNA vaccines is on its way

Adding a photocopier gene to mRNA vaccines could make them last longer and curb side effects.

Ready, set, grow: These are the biotech plants you can buy now

For $73, I bought genetically modified tomato seeds and a glowing petunia.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.